On March 17, 2022 in Geneva, Switzerland, news was released that the Medicines Patent Pool (MPP) had signed agreements with 35 manufacturers in 12 countries to produce and supply Nirmatrelvir/Ritonavir.
This is all to take steps towards supplying Covid-19 treatment to the masses.
The CDC now recommend Nirmatrelvir with Ritonavir (Paxlovid) which is supplied by none other than the world’s Big-Pharma giant; Pfizer. Pfizer signed a voluntary license deal with the MPP in November 2021.
''The limited global supply from the US means that the drugs have largely been bought by a number of high-income countries and manufacturers will not be able to bring the demanded supply to the market until 2023.''
We now, only today, are receiving pressing media coverage from Bloomberg about Covid-19 spikes regarding the World Health Organization - “WHO Chief warns of rising infections and deaths from latest Covid wave”.
Isn’t it coincidental that the WHO is now beginning to try and scare the public just in time for Pfizer to supply their Covid-19 treatment in 2023?
Is this what Big-Pharma finance foreplay looks like? They’re slowly warming the “fear factor” of Covid-19 back in to the masses.
But, why would the CDC encourage the use of this drug rather than Ivermectin?
The below is from a world renown doctor:
“I am the Director of the Evidence-based Medicine Consultancy Ltd in Bath, United Kingdom. I have a medical degree (MBBCh) and a Doctorate in Philosophy (PhD) from the University of the Witwatersrand in Johannesburg, South Africa. My United Kingdom General Medical Council registration number is 3634680.
As the director of E-BMC Ltd, which I established in 2013, I am committed to improving the quality of healthcare globally through rigorous research.”
The research that Dr Theresa Anne Lawrie conducted concluded the following:
Quick facts:
Meta-analysis of 13 trials, assessing 1892 participants, found that ivermectin reduced the risk of death by an average of 68% compared with no ivermectin treatment
Meta-analysis of 3 trials, assessing 738 participants, found that ivermectin prophylaxis among health care workers and covid-19 contacts probably reduces the risk of covid-19 infection by an average of 86%
Ivermectin has a well-established safety profile with billions of doses of ivermectin having been used worldwide for parasitic indications. Various WHO documents on parasitic infections refer to ivermectin’s long safety record.
Ivermectin is affordable, and can be distributed by various means, e.g. post, and self-administered. It can therefore effectively reach traditionally ‘hard-to-reach’ and vulnerable populations such as undocumented migrants, homeless, the elderly living alone or in care homes, those lacking transport to reach health facilities, and those who lack access to adequate health care for other reasons.
Now… what possible motive does Big-Pharma and the CDC have to push this new Pfizer-encouraged drug rather than Ivermectin (which is a cheaper, better drug)?
We the people.
P.T.Penrose,
Journalist at NVTV.
